A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale

被引:321
作者
Eton, DT
Cella, D
Yost, KJ
Yount, SE
Peterman, AH
Neuberg, DS
Sledge, GW
Wood, WC
机构
[1] Evanston NW Healthcare, Evanston, IL 60201 USA
[2] Northwestern Univ, Feinberg Sch Med, Evanston, IL 60201 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Indiana Univ, Med Ctr, Indianapolis, IN USA
[5] Emory Univ, Atlanta, GA 30322 USA
关键词
breast cancer; minimal important difference; quality of life; health-related; Functional Assessment of Cancer Therapy-Breast questionnaire; clinical significance;
D O I
10.1016/j.jclinepi.2004.01.012
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: To determine distribution- and anchor-based minimal important difference (MID) estimates for four scores from the Functional Assessment of Cancer Therapy-Breast (FACT-B): the breast cancer subscale (BCS), Trial Outcome Index (TOI), FACT-G (the general version), and FACT-B. Study Design and Setting: We used data from a Phase III clinical trial in metastatic breast cancer (ECOG study 1193; n = 739) and a prospective observational study of pain in metastatic breast cancer (n = 129). One third and one half of the standard deviation and I standard error of measurement were used as distribution-based criteria. Clinical indicators used to determine anchor-based differences included ECOG performance status, current pain, and response to treatment. Results: FACT-B scores were responsive to performance status and pain anchors, but not to treatment response. By combining the results of distribution- and anchor-based methods, MID estimates were obtained: BCS = 2-3 points, TOI = 5-6 points, FACT-G = 5-6 points, and FACT-B = 7-8 points. Conclusion: Distribution- and anchor-based estimates of the MID do show convergence. These estimates can be used in combination with other measures of efficacy to determine meaningful benefit and provide a basis for sample size estimation in clinical trials. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:898 / 910
页数:13
相关论文
共 46 条
[1]  
[Anonymous], 1996, J Clin Oncol, V14, P671
[2]  
[Anonymous], 2003, CANC FACTS FIG
[3]  
Ashing-Giwa K, 1999, CANCER, V85, P418, DOI 10.1002/(SICI)1097-0142(19990115)85:2<418::AID-CNCR20>3.0.CO
[4]  
2-9
[5]  
ASHINGGIWA K, 1999, CANCER, V86, P732
[6]   Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an eastern cooperative oncology group trial [J].
Bonomi, P ;
Kim, KM ;
Fairclough, D ;
Cella, D ;
Kugler, J ;
Rowinsky, E ;
Jiroutek, M ;
Johnson, D .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) :623-631
[7]   Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument [J].
Brady, MJ ;
Cella, DF ;
Mo, F ;
Bonomi, AE ;
Tulsky, DS ;
Lloyd, SR ;
Deasy, S ;
Cobleigh, M ;
Shiomoto, G .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) :974-986
[8]   Primary care - Primary care for survivors of breast cancer [J].
Burstein, HJ ;
Winer, EP .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (15) :1086-1094
[9]   Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of cancer therapy (FACT) anemia and fatigue scales [J].
Cella, D ;
Eton, DT ;
Lai, JS ;
Peterman, AH ;
Merkel, DE .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2002, 24 (06) :547-561
[10]   What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) study 5592 [J].
Cella, D ;
Eton, DT ;
Fairclough, DL ;
Bonomi, P ;
Heyes, AE ;
Silberman, C ;
Wolf, MK ;
Johnson, DH .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2002, 55 (03) :285-295